DHE Nasal Powder Effective for Migraine Pain Relief, Regardless of Aura Presence, Clinical Trial Shows

A recent clinical trial assessed a dihydroergotamine (DHE) nasal powder and found it to be well-tolerated and effective in reducing pain for individuals experiencing migraine, regardless of whether they also experienced aura. Specifically, the clinical trials indicated that patients using the DHE nasal powder reported both a positive safety profile and quick relief from migraine pain, whether or not they experienced aura symptoms alongside their migraines. The study focused on the effects of the nasal powder in those who have migraine.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Related posts:

Liposomal Annamycin Shows Synergistic Activity Against Leukemia, Lymphoma, Breast, Lung, and Colon Cancers in Preclinical Models When Combined with Chemotherapies Liposomal Annamycin Shows Synergistic Anti-Cancer Activity with Existing Chemotherapies in Preclinical Hematologic and Solid Tumor Models Pharma M&A Deal Value Jumps 101% in Q1 2025, Fueled by Oncology Focus European Commission Invests $565 Million to Strengthen Scientific Workforce Amid Global Competition

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後